GlucoTrack (GCTK) AI Stock Analysis

• Market Cap: $4.12M
• Dividend Yield: N/A
• Average Volume (3M): 6.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: -94.61%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -68.06
• Shares Outstanding: 28,642,809
• 10 Day Avg. Volume: 2,334,644
• 30 Day Avg. Volume: 6,070,260
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.34
• Enterprise Value/Market Cap: -1.16
• Enterprise Value/Revenue: -56.84
• Enterprise Value/Gross Profit: 596.81
• Enterprise Value/Ebitda: 0.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

GlucoTrack's overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company's current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.

GlucoTrack Business Overview & Revenue Model

Company Description

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

How the Company Makes Money

GlucoTrack generates revenue primarily through the sale of its non-invasive glucose monitoring devices. The company's key revenue streams include direct sales of its products to consumers and healthcare providers, as well as potential licensing agreements and partnerships with other medical device companies or healthcare institutions. Additionally, GlucoTrack may explore subscription-based models for device usage and data management services, providing a recurring revenue stream. Strategic partnerships with diabetes care organizations and healthcare providers can also contribute to its earnings by expanding the market reach and adoption of its technology.

GlucoTrack Financial Statement Overview

Summary

GlucoTrack faces substantial financial challenges, characterized by a lack of revenue, negative equity, and persistent cash flow deficits. While recent financing activities have temporarily bolstered cash reserves, the lack of operational revenue and continuous losses highlight significant uncertainty about future financial stability and growth potential.

Income Statement

The company has not generated any revenue since 2020, indicating significant challenges in its operations or market conditions. The net income for 2024 shows a positive figure, but this is due to adjustments or one-off events rather than operational profitability, as EBIT and EBITDA remain negative historically.

Balance Sheet

The balance sheet reveals high financial instability with negative stockholders' equity in recent years, reflecting an excess of liabilities over assets. The debt-to-equity ratio cannot be calculated due to negative equity, presenting a concerning financial structure. Cash reserves have improved, but the equity ratio remains unfavorable, signaling potential risks.

Cash Flow

While operating cash flow is consistently negative, the company has managed to maintain liquidity through significant financing activities, as seen in 2024. The free cash flow remains heavily negative, indicating ongoing cash burn, but the influx of financing cash suggests some ability to support operations in the short term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-8.00K	0.00	-13.00K	-23.00K	-42.00K	-47.00K
	EBIT
-26.48M	-14.55M	-7.10M	-4.43M	-4.04M	3.13M
	EBITDA
-17.80M	-21.98M	-7.09M	-4.41M	-4.00M	-3.08M
	Net Income Common Stockholders
-12.84M	22.60M	-7.10M	-4.44M	-4.10M	-2.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.10M	5.62M	4.49M	2.31M	6.06M	9.82M
	Total Assets
9.61M	5.93M	4.91M	2.44M	6.26M	10.61M
	Total Debt
52.00K	267.00K	196.00K	195.00K	250.00K	363.00K
	Net Debt
-9.05M	-5.35M	-4.30M	-2.12M	-5.81M	-9.46M
	Total Liabilities
2.35M	18.93M	1.71M	1.21M	1.11M	1.62M
	Stockholders Equity
7.26M	-13.00M	3.20M	1.23M	5.16M	8.98M
Cash Flow		Free Cash Flow
-12.54M	-12.59M	-6.56M	-3.73M	-3.77M	-3.55M
	Operating Cash Flow
-12.49M	-12.49M	-6.56M	-3.73M	-3.77M	-3.50M
	Investing Cash Flow
-54.00K	-104.00K	0.00	1.00K	-1.00K	-53.00K
	Financing Cash Flow
20.14M	13.74M	8.73M	0.00	0.00	13.01M

GlucoTrack Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.16, and below the 200-day MA of 15.07, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.56 is Neutral, neither overbought nor oversold. The STOCH value of 48.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.

GlucoTrack Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	70 Neutral	$17.80M	1.70	7.10%	―	-0.19%	-18.41%
MLSS	54 Neutral	$71.38M	―	-88.36%	―	-9.13%	30.04%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
POAI	41 Neutral	$8.85M	―	-504.16%	―	-31.31%	49.27%
FEMY	38 Underperform	$21.79M	―	-239.87%	―	61.97%	-6.89%
GCTK	28 Underperform	$4.12M	―	-694.34%	―	―	-94.61%
STSS		$3.81M	―	-75.14%	―	―	―

GlucoTrack Corporate Events

GlucoTrack Releases Investor Presentation on April 29

On April 29, 2025, GlucoTrack, Inc. issued an investor presentation. The presentation is part of a current report on Form 8-K and is not considered filed for purposes of the Securities Exchange Act of 1934.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.

To see Spark’s full report on GCTK stock, click here.

GlucoTrack Joins EU Bionic Pancreas Initiative

On April 16, 2025, Glucotrack announced its participation in the FORGETDIABETES bionic pancreas initiative, a European Union-funded project aimed at developing an automated insulin delivery system for optimal glucose control without patient intervention. This collaboration is expected to revolutionize diabetes management by integrating Glucotrack’s Continuous Blood Glucose Monitor with the bionic pancreas system, potentially transforming diabetes from a disease requiring constant attention into a more manageable lifestyle condition.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

GlucoTrack’s stock score reflects significant financial and technical weaknesses, primarily due to the lack of revenue and a downward price trend. However, positive developments from recent corporate events, including strategic partnerships and clinical advancements, provide some optimism for potential future growth. The company’s current valuation is poor, but strategic moves could attract speculative interest if financial and operational hurdles are addressed.

To see Spark’s full report on GCTK stock, click here.

GlucoTrack Partners with OneTwo Analytics for AI-Driven Insights

On April 3, 2025, Glucotrack announced a strategic agreement with OneTwo Analytics AB to enhance the analysis of clinical study data from its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. This collaboration aims to improve insights into the CBGM’s performance and clinical value, potentially revolutionizing diabetes management by providing a more convenient and less intrusive glucose monitoring solution. The partnership is expected to deliver a comprehensive ecosystem combining blood glucose insights, risk stratification data, and patient engagement tools, thereby improving care for millions of people with diabetes.

GlucoTrack Advances with Clinical Trials and Funding Boost

GlucoTrack reported its financial results for 2024, highlighting a transformative year as it moved from a preclinical to a clinical stage company. The company strengthened its leadership team and secured significant funding to support its growth and clinical development. Key achievements included the successful completion of the first human clinical study of its CBGM technology and obtaining ISO certification, positioning the company for further advancements in 2025. Despite increased expenses leading to a higher net loss, GlucoTrack’s financial position was bolstered by multiple funding rounds, providing a runway for upcoming milestones.

GlucoTrack to Present Data on New Glucose Monitoring System

On March 19, 2025, Glucotrack announced that it will present safety and performance data from its first-in-human trial of its continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes in Amsterdam. The CBGM system, which measures glucose directly from the blood without on-body wearables, is designed for long-term use and aims to offer more accurate and less intrusive glucose monitoring. This presentation marks a significant step in advancing Glucotrack’s clinical program and could potentially transform diabetes management.

GlucoTrack Appoints Dr. Umpierrez to Advisory Board

On February 26, 2025, Glucotrack, Inc. announced the appointment of Dr. Guillermo Umpierrez, a leading diabetes researcher and clinician, to its Medical Advisory Board. This strategic move is expected to enhance the company’s development of its innovative Continuous Blood Glucose Monitoring (CBGM) technology, which aims to improve diabetes care by offering a less intrusive and more accurate monitoring solution. Dr. Umpierrez’s extensive experience in diabetes research and care will be instrumental as Glucotrack progresses into human clinical trials, potentially strengthening its position in the diabetes care industry and offering significant advancements for stakeholders.

GlucoTrack’s $3.03M Stock Offering Agreement Announced

On February 4, 2025, Glucotrack, Inc. entered a securities purchase agreement with institutional investors to offer and sell approximately 2.6 million shares of its common stock at $1.15 per share. The offering is expected to generate gross proceeds of approximately $3.03 million, which the company plans to use for working capital and general corporate purposes. The closing of the offering is anticipated by February 5, 2025, with Dawson James Securities, Inc. acting as the placement agent. The agreement restricts the company from issuing additional shares or entering certain transactions for 30 days following the offering’s closure, while directors and executives will adhere to a 180-day lock-up period.